Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart glucose monitor plus online dietitian could transform diabetes care

NCT ID NCT06888687

Disease control Sponsor: Australian Catholic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a continuous glucose monitor (CGM) along with remote dietitian support helps people with type 2 diabetes better control their blood sugar. About 160 adults across Australia will use a CGM and receive online dietary advice for several months. The goal is to see if this approach lowers HbA1c (a key blood sugar measure) and improves daily glucose levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

160 people

The number who actually took part.

Started

May 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18+ years * Reside anywhere in Australia and have a postal address * Confirmed T2D diagnosis by a GP/endocrinologist * Current HbA1c of ≥7.0% * Have a smartphone and able to independently use it Exclusion Criteria: * Under the age of 18 years * Use of insulin therapy (within the last three months) or medications which interfere with blood glucose levels (i.e. steroids) * Use of CGM within the last six months * Eating Disorder Examination Questionnaire (EDE-Q) global score \>2.8 OR global score \> or equal to 1.52, with sum of Q14-18 \> or equal to 4 * Currently having ongoing consultations with an APD or have had a consult with an APD (within last three months) * Not weight stable (\>5 kg change over last three months) * Severe hypoglycaemic event (i.e. requiring assistance) within last six months * Change of antihyperglcyaemic medications within last three months * Women who are pregnant or breastfeeding (within 24 weeks) * History of psychotic disorder, or current diagnosis of other major psychiatric illness (e.g. mood disorder, eating disorder, substance use disorder) * History of blood disorders (including but, not limited to, anemia and thalassemia) that impact the primary outcome (HbA1c)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose measurement are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Continuous glucose measurement Dietary modification Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Australian Catholic University

    Melbourne, Victoria, 3065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.